好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Predicting Falls in People with Multiple Sclerosis: Keep It Simple
MS and Related Diseases
P04 - (-)
100
BACKGROUND: Many people with MS fall and many tests may identify those at risk for falls, but the ideal test for identifying those at risk for falls is not known.
DESIGN/METHODS: 52 people with MS were asked, "Have you fallen in the past 2 months?" and, "Have you fallen in the past year?" They also completed the Activities-specific Balance Confidence (ABC), Falls Efficacy Scale-International (FES-I), and Multiple Sclerosis Walking Scale-12 questionnaires, were evaluated with computerized dynamic posturography and completed daily fall diaries for the following 6 months. The ability of all tests to predict future falls was evaluated using ROC curves and logistic regression.
RESULTS: All tests individually provided similar prediction of falls in the ensuing 2 or 6 months (AUC 0.62 - 0.75). No method individually was more accurate than simply querying the patient about falls experienced in the past. The best prediction of falls over the following 2 months was provided by combining a history of one or more falls in the past 2 months with the ABC score (AUC 0.82). The best prediction of falls over the following 6 months was provided by a history of one or more falls over the past year (AUC 0.73).
CONCLUSIONS: Simply asking people with MS if they have fallen in the past 2 months and past year predicts future falls as well as more complex, expensive or time-consuming approaches. Clinicians should consider asking their MS patients whether they have fallen in the past 2 months and year as an easy way to identify patients at risk for falling.
Authors/Disclosures
Michelle Cameron, MD (Oregon Health and Science University)
PRESENTER 		Dr. Cameron has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Greenwich Biosciences/Jazz . Dr. Cameron has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Adamas Pharmaceuticals. Dr. Cameron has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer. The institution of Dr. Cameron has received research support from National MS Society. The institution of Dr. Cameron has received research support from Department of Veterans Affairs. Dr. Cameron has received publishing royalties from a publication relating to health care.
Dennis N. Bourdette, MD, FAAN Dr. Bourdette has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Magellan Health Care. Dr. Bourdette has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Best Doctor's Inc. Dr. Bourdette has stock in Authobahn Therapeutics. Dr. Bourdette has received intellectual property interests from a discovery or technology relating to health care.
Mark S. Freedman, MD, FAAN (University of Ottawa) Dr. Freedman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Actelion(Janssen/J&J). Dr. Freedman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BiogenIdec. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS/Celgene. Dr. Freedman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD Inc. Dr. Freedman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Freedman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Actelion (Janssen/J&J). Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Atara Biotherapeutics. Dr. Freedman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Bayer Healthcare. Dr. Freedman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for BiogenIdec. Dr. Freedman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Clene Nanomedicine. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GRI Bio. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Magenta Therapeutics. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck Serono. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Freedman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi Genzyme. Dr. Freedman has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sanofi Genzyme. Dr. Freedman has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. The institution of Dr. Freedman has received research support from Sanofi Genzyme.